Decoding 13 Analyst Evaluations For Elevance Health
Portfolio Pulse from Benzinga Insights
Analyst ratings for Elevance Health (NYSE:ELV) show a mix of bullish to bearish sentiments among 13 analysts over the last quarter, with a positive shift in the 12-month price targets to an average of $586.0. The company, a leading health insurer in the U.S., has seen a revenue growth rate of 0.96% as of March 31, 2024, and outperforms in net margin and ROE, despite a high debt-to-equity ratio.
April 24, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Elevance Health's analyst ratings vary, with a recent positive adjustment in price targets. The company's strong financial performance and market position as a leading health insurer highlight its potential despite a high debt-to-equity ratio.
The positive shift in analyst ratings and price targets, combined with Elevance Health's solid financial performance and strategic market position, suggest a likely upward movement in the short term. The company's revenue growth, high net margin, and ROE are indicative of strong operational efficiency and profitability, which are key drivers of stock performance. However, the high debt-to-equity ratio introduces a note of caution, potentially moderating the positive impact.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100